1 / 24

Chronische lymphatische Leukämie – Was ist neu?

Chronische lymphatische Leukämie – Was ist neu?. Michael Hallek www.dcllsg.de. CLL: Stadium bestimmt Behandlung. CLL in frühen Stadien. CLL1: DESIGN AND STUDY POPULATION (n = 630). Binet stage A 877 pts. LDT <12/>12 months BM diffuse/non diffuse. Risk Stratification 804 pts.

ulema
Download Presentation

Chronische lymphatische Leukämie – Was ist neu?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chronische lymphatische Leukämie – Was ist neu? Michael Hallek www.dcllsg.de

  2. CLL: Stadium bestimmt Behandlung

  3. CLL in frühen Stadien

  4. CLL1: DESIGN AND STUDY POPULATION (n = 630) Binet stage A 877 pts LDT <12/>12 months BM diffuse/non diffuse Risk Stratification 804 pts TK ≤/> 7 U/L ß2-MG ≤/> 3.5 mg/L Inclusion/Exclusion ok 728 pts LOW RISK 535 pts HIGH RISK W&W 95 pts n = 630 R HR Fludarabine 98 pts

  5. PFS AND OS RELATED TO RISK STRATIFICATION LR = 522; Events = 262 HR W&W = 94; Events = 75 LR = 527; Events = 42 HR W&W = 93; Events = 19 p<0.001 p<0.001

  6. PFS AND OS IN RELATION TO IGVH-STATUS + FISH p<0.001 p<0.001 p=0.054

  7. Conclusion: Top 10 variables predicting OS and PFS in untreated, early stage CLL

  8. Cox regression model (excluding cytogenetics): Overall survival

  9. Major factors predicting an unfavorable course in Binet stage A/Rai stage 0 CLL • Chromosomal aberrations 17p- and 11q- • Elevated serum thymidine kinase (> 10 U/L) • Lymphocyte doubling time < 12 months • Unmutated IgVH gene • Expression of cytoplasmic ZAP70 • Elevated surface expression of CD38?

  10. CLL7 protocol of the GCLLSG/FCLLSGPatients at Binet stage A or B without symptoms Aim and Rationale: Complete (MRD-) eradication of early high risk disease • Assessment of 4 prognostic factors: • 11q- or 17p- deletion • Unmutated IgVH-Status • Serum thymidine kinase > 10 U/L • Lymphocyte doubling time < 12 months Low risk: < 2 factors positive watch and wait 2/3 of patients FCR High risk: 2 or more factors positive watch and wait 1/3 of patients

  11. Ältere (komorbide) Patienten mit CLL in fortgeschrittenen Stadien

  12. CLL5 protocol for elderly patients with advanced CLL CLL,> 65 years, untreated, Binet stage C or symptomatic A/B 6 x Fludarabine phosphate F 25 mg/m², Days 1–5q 28 days Chlorambucil (up to a maximum of 12 months) Clb0.4 mg/kg body weight increasing 0.1 mg up to 0.8 mg/kg body weight q 15 days

  13. CLL5 protocol Overall Survival (OS) p = 0.15 Median OS: F 45.8 months; Clb 63.6 months

  14. CLL5 protocolCauseofdeath Clb arm: 32 patients died F arm: 42 patients died

  15. Jüngere (fitte) Patienten mit CLL in fortgeschrittenen Stadien

  16. p=0.16 p=0.10 p<0.01 p=0.12 First-line R-FC: improved OSfollowing CR 1.0 0.8 0.6 Probability 0.4 0.2 0 0 12 24 36 48 60 72 84 96 108 Time (months) nPR = nodular PRPR-i = met all criteria for CR except for incomplete recovery of blood countsPR-d = residual disease in blood, nodes, spleen, marrow or other sites Tam CS, et al. Blood 2008;112:975–80

  17. p<0.001 p=0.37 F±P vs F±M/C vs R-FC: improved survival with rituximab (historical comparison) 1.0 0.8 0.6 Probability 0.4 0.2 0 0 12 24 36 48 60 72 84 96 108 Time (months) Tam CS, et al. Blood 2008;112:975–980

  18. CLL8: first-line treatment of CLL 6 x FCR Final staging and follow-up 817 untreated patients with Binet B/C CLL randomised 6 x FC Final staging and follow-up • In January 2008, the DSMB concluded that the study had reached the primary endpoint (PFS, difference of at least 35% at 2 yrs) • FCR is the superior study arm

  19. Protocol amendment 1 Second to fourth-line therapy First-line therapy 81 patients 119 patients 6 cycles BR 6 cycles BR Bendamustine 70mg/m2 day 1-2 q4wks, cycle 1-6 Rituximab 375 mg/m2 day 0, cycle 1 500 mg/m2 cycle 2-6 Bendamustine 90mg/m2 day 1-2 q4wks, cycle 1-6 Rituximab 375 mg/m2 day 0, cycle 1 500 mg/m2 cycle 2-6 CLL2M study design II closed closed

  20. BR GCLLSG – FCR Wierda

  21. BR GCLLSG – FCR Wierda

  22. CLL 10 protocol of GCLLSG Fludarabin Cyclophosphamid Rituximab (FCR) Fludarabine 25 mg/m² i.v., days 1-3 Cyclophosphamide 250 mg/m², days 1-3, Rituximab: 375 mg/ m2 i.v. day 0, cycle 1 Rituximab: 500 mg/m² i.v. day 1, cycle 2-6 R Bendamustin Rituximab (BR) Bendamustine 90mg/m² day 1-2 Rituximab 375 mg/m² day 0, cycyle 1 Rituximab 500 mg/m² day 1, cycyle 2-6 Similar efficacy of BR in comparison to FCR? Lower toxicity rate of BR?

  23. 3rd generation of trials of the GCLLSG: Risk, stage and fitness adapted Inactive Binet A Active disease + all Binet C, not del(17p) CLL12 CLL10 CLL11 Which is the best score to define high risk? Go Go Slow go no yes W&W W&W treat BR FCR CLB CLB + R Disease (MRD) eradication? Longer survival? Symptom control? longer disease-free survival?

  24. CLL Treatment 2008

More Related